INSTANT-VIEW MDMA (ECSTASY, XTC) URINE TEST

K022501 · Alfa Scientific Designs, Inc. · DJC · Nov 13, 2002 · Clinical Toxicology

Device Facts

• Record ID: K022501
• Device Name: INSTANT-VIEW MDMA (ECSTASY, XTC) URINE TEST
• Applicant: Alfa Scientific Designs, Inc.
• Product Code: DJC · Clinical Toxicology
• Decision Date: Nov 13, 2002
• Decision: SESE
• Submission Type: Abbreviated
• Regulation: 21 CFR 862.3610
• Device Class: Class 2

Intended Use

This device is a one-step immunoassay intended to provide qualitative detection of methylenedioxymethamphetamine (MDMA, also Ecstasy, or XTC) in human urine at a cutoff concentration of 500ng/ml. It is for health care professional use only. This test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Device Story

Instant-View™ MDMA Urine Test is a lateral flow chromatographic immunoassay for qualitative detection of MDMA in human urine. Device consists of a test strip with a conjugate pad containing colloidal gold-labeled mouse anti-MDMA antibody and a nitrocellulose membrane with a test line (MEMA-BSA) and a control line (Goat anti-mouse antibody). Used in clinical settings by healthcare professionals; provides preliminary results. Sample application triggers capillary flow; competitive binding occurs between MDMA in urine and immobilized MEMA-BSA for gold-labeled antibodies. Absence of test line indicates positive result; presence of control line validates test performance. Results require confirmation via GC/MS. Assists clinicians in identifying potential MDMA presence to guide further diagnostic or clinical management.

Clinical Evidence

Accuracy evaluated using 80 clinical urine specimens compared against GC/MS. Overall agreement was 97.5% (100% agreement at levels <75% of cutoff and >cutoff; 2 discrepancies observed between 75% and 100% of cutoff). Reproducibility tested at three Physician's Office Laboratories (POL) and one reference lab by personnel with diverse experience; 97.5% agreement achieved. Specificity testing showed cross-reactivity with MDA (2000 ng/mL) and MDEA (1000 ng/mL); no interference from other structurally related compounds at 100 µg/mL.

Technological Characteristics

Lateral flow chromatographic immunoassay. Components: conjugate pad (colloidal gold-labeled mouse anti-MDMA antibody), nitrocellulose membrane (test line: MEMA-BSA; control line: Goat anti-mouse antibody). Qualitative, visual readout. Standalone, single-use device. No external energy source required.

Indications for Use

Indicated for qualitative detection of MDMA (Ecstasy/XTC) in human urine at 500 ng/mL cutoff. For use by healthcare professionals only. Provides preliminary results requiring confirmation by GC/MS.

Regulatory Classification

Identification

A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose.

Special Controls

*Classification.* Class II (special controls). A methamphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• Microgenics A-Sure™ Ecstasy Drug Screen Test (K011133)

Submission Summary (Full Text)

{0}------------------------------------------------

## NOV 1 3 2002

## 510(k) Summary of Safety and Effectiveness as Required by 21 CFR 807.92

| Submitter and<br>manufacture | Name: Alfa Scientific Designs, Inc.<br>Address: 12330 Stowe Drive<br>Poway, CA 92064<br>Contact Person: Naishu Wang, MD, Ph.D.<br>Telephone: [phone] x 308<br>Fax: [phone]<br>E-mail: [e-mail] |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name | Trade Name: Instant-View™ MDMA (Ecstasy, XTC) Urine Test<br>Common Name: Immunoassay, MDMA Urine Test<br>Classification: Amphetamine Test System (21 CFR 862.3100)<br>Class II |
| Date of Summary<br>Preparation | October 28, 2002 |
| Predicate Device | Microgenics A-Sure™ Ecstasy Drug Screen Test made by<br>Applied Biotech, Inc. K011133 |
| Device Description | A one-step lateral flow chromatographic immunoassay. The<br>test strip in the device includes 1) a conjugate pad containing<br>colloidal gold coupled with mouse anti-MDMA antibody; 2)<br>nitrocellulose membrane containing a test line (T line) coated<br>with MEMA-BSA and a control line (C line) coated with Goat<br>anti mouse antibody. |
| Similarity to the<br>Predicate Device | • Both are one-step later-flow chromatographic immunoassay.<br>• Both are used for qualitative detection of MDMA (Ecstasy, XTC) at a cutoff of 500 ng/ml.<br>• Both are based on the similar mechanism<br>• Both use a C line as built-in control to indicate that an<br>appropriate volume of sample is applied and the device<br>performs properly.<br>• Both provide a preliminary result and a positive result needs<br>to be confirmed with a more solid reference method. |
| Intended Use | This device is a one-step immunoassay intended to provide<br>qualitative detection of methylenedioxymeth-<br>amphetamine (MDMA, also Ecstasy, or XTC) in human urine<br>at a cutoff concentration of 500ng/ml. It is for health care<br>professional use only. |
| Accuracy studies | Eighty clinical urine specimens with MDMA GC/MS data was<br>evaluated with the Instant-View™ MDMA (Ecstasy, XTC) Urine<br>Test. The results from the Instant-View™ MDMA (Ecstasy, XTC)<br>Urine Test agreed 100% with the MDMA GC/MS data of the<br>clinical specimens at the level below 75% of the cutoff and<br>above the cutoff. Two (2) discrepancies were observed on the<br>specimens with the MDMA GC/MS data between the cutoff<br>level and the level of 75% cutoff.<br><br>The overall agreement is 97.5%. |
| Reproducibility<br>studies | The reproducibility of this device was studied outside of Alfa at<br>three Physician's Office Laboratories (POL) and one reference<br>laboratory. Evaluations were performed by personnel with<br>diverse educational backgrounds and working experiences. The<br>results from the four evaluation sites agreed 97.5%, indicating<br>a high reproducibility of this device. |
| Specificity studies | Two of the structurally related compounds showed cross<br>reactivity with this device: methylenedioxyampphetamine<br>(MDA) at 2000 ng/ml and methylenedioxyethylamphetamine<br>(MDEA) at 1000 ng/ml. Other structurally related compounds<br>tested did not show cross reactivity or interference with this<br>device at the concentration of 100 µg/ml. |
| Conclusion | The results of accuracy, reproducibility, and specificity studies<br>demonstrate that the Instant-View™ MDMA (Ecstasy, XTC)<br>Urine Test is substantially equivalent to the legally marketed<br>test. |

・

{1}------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image is a circular seal for the Department of Health & Human Services - USA. The seal features the department's logo, which is a stylized caduceus with three intertwined snakes. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the logo in a circular fashion.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

## NOV 1 3 2002

Naishu Wang, M.D., Ph.D. . President Alfa Scientific Designs, Inc. 12330 Stowe Drive Poway, CA 92064

Re: k022501

> Trade/Device Name: Instant-View™ MDMA (Ecstasy, XTC) Urine Test Regulation Number: 21 CFR 862.3610 Regulation Name: Methanphetamine test system Regulatory Class: Class II Product Code: DJC Dated: October 28, 2002 Received: October 31, 2002

Dear Dr. Wang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and i additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510 (K) NUMBER (IF KNOWN) :

DEVICE NAME : Instant-View" MDMA (Ecstasy, XTC) Urine Test

## INDICATIONS FOR USE:

This device is a one-step intended to provide qualitative rapid detection of methylenedioxymethamphetamine (MDMA, or Ecstasy, XTC) in human urine at a cut-off concentration of 500ng/ml. It is for health care professional use only.

This test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED . )

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

OR

Over-The-Counter Use (Optional Format 1-2-96)

Sean Cooper

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K022501